title: Association study of interferon gamma (IFN-γ) +874T/A gene polymorphism in patients with paranoid schizophrenia.
abstract: Schizophrenia is a multifactorial disease with changes affecting the immune system. Dysregulation of the cytokine network in schizophrenia has been well documented. Such changes may occur due to disturbances in cytokine levels that are linked to polymorphisms of cytokine genes. However, research in the role of cytokine gene polymorphisms in schizophrenia has been surprisingly scanty. The aim of this study was to identify, in a case control study, whether polymorphism of IFN-γ gene is a risk factor for the development of paranoid schizophrenia. To the best of our knowledge, this is the first study that examines the association between the IFN-γ gene polymorphism and psychopathological symptoms in patients with paranoid schizophrenia. Polymorphism of IFN-γ (+874T/A, rs 62559044) in schizophrenic patients (n=179), as well as healthy individuals (n=196), both Polish residents, was genotyped using AS-PCR method. Of note, when analyzing the results, we took into consideration the gender of studied individuals. Surprisingly, a single-nucleotide polymorphism in the first intron of the IFN-γ gene was found to be associated with paranoid schizophrenia in males, but not in females. The presence of allele A at position +874 in the IFN-γ gene correlates with 1.66-fold higher risk of paranoid schizophrenia development in males. Differences in the genotypes may have an important role in determining the level of I gene transcription. Because other polymorphisms have been demonstrated to influence IFN-γ transcription, further analysis is necessary to clarify the role of this gene in the pathogenesis of paranoid schizophrenia.
authors.affiliation: Department of Medical Genetics, Medical University of Silesia, 30, Ostrogorska Street, 41-200, Sosnowiec, Poland. mpaul@sum.edu.pl
authors.forename: Monika
authors.initials: M
authors.lastname: Paul-Samojedny
authors.forename: Aleksander
authors.initials: A
authors.lastname: Owczarek
authors.forename: Renata
authors.initials: R
authors.lastname: Suchanek
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Kowalczyk
authors.forename: Anna
authors.initials: A
authors.lastname: Fila-Danilow
authors.forename: Paulina
authors.initials: P
authors.lastname: Borkowska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Kucia
authors.forename: Jan
authors.initials: J
authors.lastname: Kowalski
mesh_terms: D000328:Adult; D000483:Alleles; D016022:Case-Control Studies; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007371:Interferon-gamma / Q000235:genetics*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011044:Poland; D020641:Polymorphism, Single Nucleotide; D012563:Schizophrenia, Paranoid / Q000235:genetics*; D055815:Young Adult
chemical_list: D007371:Interferon-gamma
references.citation: Curr Pharm Des. 2005;11(8):1017-30
references.pmid: 15777251
references.citation: Hum Immunol. 2000 Sep;61(9):863-6
references.pmid: 11053629
references.citation: Clin Neurosci Res. 2006 Aug;6(1-2):52-68
references.pmid: 18079991
references.citation: Cytokine Growth Factor Rev. 2009 Feb;20(1):43-59
references.pmid: 19038572
references.citation: Psychiatry Res. 1997 Feb 7;66(2-3):145-52
references.pmid: 9075278
references.citation: J Korean Med Sci. 2009 Dec;24(6):1083-8
references.pmid: 19949664
references.citation: Biol Psychiatry. 1994 Apr 1;35(7):464-73
references.pmid: 7517191
references.citation: Ann N Y Acad Sci. 1998 Sep 29;856:22-32
references.pmid: 9917861
references.citation: Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:17-54
references.pmid: 12650680
references.citation: Acta Psychiatr Scand Suppl. 2000;401:3-38
references.pmid: 10887978
references.citation: Arch Neurol. 2008 Mar;65(3):349-57
references.pmid: 18332247
references.citation: Am J Psychiatry. 1996 Sep;153(9):1178-84
references.pmid: 8780422
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):1007-12
references.pmid: 14499318
references.citation: Mol Psychiatry. 1999 Jul;4(4):302-6
references.pmid: 10483041
references.citation: J Mol Neurosci. 2010 Sep;42(1):112-9
references.pmid: 20393813
references.citation: J Neurosci. 2002 Jun 1;22(11):4530-9
references.pmid: 12040060
references.citation: Psychoneuroendocrinology. 2009 Apr;34(3):382-8
references.pmid: 18990498
references.citation: Curr Pharm Des. 2005;11(8):973-84
references.pmid: 15777248
references.citation: Expert Rev Clin Immunol. 2005 May;1(1):103-12
references.pmid: 20477658
references.citation: Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:83-96
references.pmid: 12650683
references.citation: Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7016-20
references.pmid: 1908086
references.citation: Am J Psychiatry. 1985 Oct;142(10):1184-6
references.pmid: 2412455
references.citation: Mol Biol Med. 1990 Aug;7(4):323-31
references.pmid: 2122173
references.citation: Clin Psychol Rev. 1998 Nov;18(7):795-819
references.pmid: 9827322
references.citation: Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R125-33
references.pmid: 12952866
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Int J Dev Neurosci. 1997 Oct;15(6):711-6
references.pmid: 9402221
references.citation: Mol Psychiatry. 2000 Nov;5(6):594-603
references.pmid: 11126390
references.citation: Immunol Lett. 1988 Mar;17(3):267-71
references.pmid: 2453456
references.citation: Am J Psychiatry. 2000 May;157(5):683-94
references.pmid: 10784457
references.citation: Schizophr Res. 2008 Sep;104(1-3):237-45
references.pmid: 18573639
references.citation: J Med Genet. 2005 Mar;42(3):193-204
references.pmid: 15744031
references.citation: Schizophr Res. 2001 Jul 1;50(3):169-75
references.pmid: 11439237